Company: Dr. Reddy's Laboratories Ltd. Category: Broker Research

DRRD launched gSuboxone sublingual films post approval in all the four dosage strengths from USFDA
June 15, 2018, 3:59 p.m.

Motilal Oswal stays Neutral on Dr Reddy’s Labs
June 15, 2018, 12:23 p.m.

We believe the stock will remain range bound until there is more visibility on key launches in the US (including Aloxi, Nuvaring, Soboxone, and Copaxone 20 and 40mg). Maintain Neutral with a target price of...
Oct. 5, 2017, 5:16 p.m.

Dr Reddy’s Labs: Maintain Neutral with a target price of Rs.2400
Oct. 5, 2017, 10:19 a.m.

Dr Reddy’s Laboratories (DRRD) has been under dark clouds - delays in approvals, regulatory overhangs and intensifying competition, culminating in a sharp 46% dip in FY17 earnings.
Sept. 21, 2017, 12:38 p.m.

Motilal Oswal recommend 'Neutral' on Dr.Reddy's Labs due to no revenue impact post no supply to EU
Sept. 11, 2017, 12:01 p.m.

Dr. Reddy’s Laboratories: Company Update - Nirmal Bang
Sept. 5, 2017, 12:40 p.m.
Author : Nirmal Bang | Publisher:

Dr. Reddy's Labs: Maintain Neutral, says Motilal Oswal
Sept. 4, 2017, 9:30 a.m.

  • 1